Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yiwei Oral Liquid is a Traditional Chinese Medicine (TCM) formulation developed by the Department of Integrated Traditional Chinese and Western Medicine at West China Hospital, Sichuan University. It is primarily indicated for the treatment of epigastric fullness syndrome characterized by spleen and stomach deficiency, particularly in patients who have undergone chemotherapy for malignant tumors. The formulation is designed to tonify the spleen and nourish stomach yin, addressing common gastrointestinal side effects of cancer treatment such as bloating, loss of appetite, and digestive weakness. It has been evaluated in randomized, single-blinded, placebo-controlled clinical trials to assess its efficacy and safety in improving the quality of life and nutritional status of post-chemotherapy patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yiwei Oral Liquid.